Tallac Therapeutics Appoints Curtis Hecht as Chief Business Officer

Logo
April 15, 2021 12:00 UTC

 

 
 

BURLINGAME, Calif.--(BUSINESS WIRE)-- Tallac Therapeutics, Inc. (“Tallac”), a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced the appointment of Curtis Hecht as Chief Business Officer

“We are delighted to welcome Curtis to Tallac. Curtis’s extensive industry experience spearheading research and development collaborations and partnerships will be invaluable to Tallac as we advance multiple assets from our novel TRAAC platform,” said Hong I. Wan, Ph.D., President, Chief Executive Officer and co-founder of Tallac.

Curtis Hecht joins the company with over 25 years of leadership, corporate strategy and business development experience, most recently from Calithera Biosciences, Inc. where he served as Chief Business Officer. Previously, Curtis held senior business development roles at various life sciences and biotechnology companies including DNA Ink, inVentiv Health, Genentech and Roche. Reporting to the Chief Executive Officer, and in partnership with the Management Team and Board of Directors, Curtis will play a lead role in the development and execution of near-term and long-range strategy for Tallac.

“Cancer immunotherapy holds significant promise for patients and Tallac’s unique approach employing both the adaptive and innate immune systems has potential to be transformative, “ said Curtis Hecht. “I’m excited at the opportunity to work with the exceptional team at Tallac during this pivotal phase of its growth.”

About Tallac

Tallac Therapeutics is a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer. Tallac’s pipeline of immunotherapy candidates are derived from the company’s novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform to deliver a potent Toll-like receptor (TLR9) agonist (T-CpG) for targeted immune activation via systemic administration. Several TRAAC molecules are in various stages of discovery and preclinical development. For more information, please visit www.tallactherapeutics.com.

Contacts

Tallac Therapeutics
Media Contact:
Tara Cooper
The Grace Communication Group
650-303-7306
tara@gracegroup.us

 
 

Source: Tallac Therapeutics, Inc.

Back to news